Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

3.08 

-0.09 -2.8%

as of Nov 15 '19

52 Week Range:

0.91 4.36


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy. The company has a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP); and Best disease and other bestrophinopathies. It also has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach to create AAV gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and STGD1; and to evaluate various AAV gene delivery methods for potential application in the eye. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 6.01
5.17
2.36
-1.02
1.22
0.13
growth rate -14.0% -54.4% -100.0% 100.0% -89.3%
Earnings BIT -123.53
-195.56
114.51
-58.45
growth rate 0.0% 100.0% -100.0%
Avg.PE 0.64
growth rate
ROA -329.58
-343.05
-51.25
-27.42
-22.80
-53.10
48.07
40.34
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -16.1%
ROE -263.75
-61.98
-102.11
77.89
growth rate 0.0% 0.0% 100.0%
ROIC -263.75
-61.98
-102.11
74.99
growth rate 0.0% 0.0% 100.0%
Cur. Ratio 2.25
0.34
34.54
23.88
8.17
4.49
13.68
10.09
growth rate -84.9% 10,058.8% -30.9% -65.8% -45.0% 204.7% -26.2%
Quick Ratio 2.23
0.30
33.45
23.42
8.03
4.44
13.43
9.94
growth rate -86.6% 11,050.0% -30.0% -65.7% -44.7% 202.5% -26.0%
Leverage 1.28
3.39
7.15
4.62
1.11
growth rate 164.8% 110.9% -19.6% -76.0%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 4.39
3.53
1.39
growth rate -19.6% -60.7%
Acct.Payable 12.02
12.03
7.55
5.87
growth rate 0.1% -37.2% -22.3%
Cur.Assets 306.49
295.89
171.51
133.29
growth rate -3.5% -42.0% -22.3%
Total Assets 428.85
299.63
175.58
137.17
growth rate -30.1% -41.4% -21.9%
Cash 221.86
133.93
166.97
131.20
growth rate -39.6% 24.7% -21.4%
Cur.Liabilities 37.51
65.92
12.54
13.21
growth rate 75.8% -81.0% 5.4%
Liabilities 368.90
394.25
137.54
13.21
growth rate 6.9% -65.1% -90.4%
LT Debt 125.00
125.00
125.00
growth rate 0.0% 0.0%
Equity 59.95
-94.62
38.04
123.96
growth rate -100.0% 100.0% 225.9%
Common Shares 1.00
1.00
9.00
33.00
35.00
35.00
36.00
37.00
growth rate 0.0% 800.0% 266.7% 6.1% 0.0% 2.9% 2.8%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 2.62
0.57
growth rate -78.1%
Cash From OA -78.53
-108.60
-121.82
-41.91
growth rate 0.0% 0.0% 0.0%
FCF per Share -1.20
2.25
-0.89
-3.29
-3.95
-1.25
growth rate 100.0% -100.0% 0.0% 0.0% 0.0%
FCF -19.00
-13.00
-49.00
109.00
-81.00
-109.00
-122.00
-42.00
growth rate 0.0% 0.0% 100.0% -100.0% 0.0% 0.0% 0.0%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 51.51
50.91
209.98
growth rate -1.2% 312.5%
Op.Income -123.53
-195.56
114.51
-58.45
growth rate 0.0% 100.0% -100.0%
IBT -122.50
-193.83
109.49
62.02
growth rate 0.0% 100.0% -43.4%
Net Income -105.72
-193.42
114.21
63.09
growth rate 0.0% 100.0% -44.8%
EPS -18.27
-14.71
-6.34
-3.51
-3.06
-5.45
3.17
1.70
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -46.4%
Gross Profit -79.51
-145.39
143.69
-34.84
growth rate 0.0% 100.0% -100.0%
R&D 66.29
66.29
66.29
growth rate 0.0% 0.0%

Quarterly Statements

Item Name Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Earnings BIT -15.38
-14.90
-13.17
-15.21
-15.06
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Acct.Receivable 1.77
growth rate
Acct.Payable 4.39
5.87
2.99
3.24
growth rate 33.7% -49.1% 8.5%
Cur.Assets 137.26
133.29
119.03
110.59
growth rate -2.9% -10.7% -7.1%
Total Assets 140.96
137.17
124.10
113.61
growth rate -2.7% -9.5% -8.5%
Cash 135.21
131.20
116.64
106.89
growth rate -3.0% -11.1% -8.4%
Cur.Liabilities 10.53
13.21
9.88
11.88
growth rate 25.4% -25.2% 20.2%
Liabilities 135.53
13.21
10.13
11.88
growth rate -90.3% -23.3% 17.3%
LT Debt 125.00
0.25
growth rate -95.6%
Equity 5.43
123.96
113.97
101.73
growth rate 2,184.1% -8.1% -10.7%
Common Shares 0.04
0.04
0.04
0.04
growth rate 13.9% 0.0% 0.0%
Cash Flow Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Cash From OA -10.82
-10.08
-14.60
-9.75
growth rate 0.0% 0.0% 0.0%
Income Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Op.Income -15.38
-14.90
-13.17
-15.21
-15.06
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -14.74
103.88
-12.50
-14.44
-14.56
growth rate 100.0% -100.0% 0.0% 0.0%
Net Income -14.75
104.11
-12.50
-14.44
-14.44
growth rate 100.0% -100.0% 0.0% 0.0%
Gross Profit -9.41
-9.23
-7.69
-10.01
growth rate 0.0% 0.0% 0.0%
R&D 7.69
10.38
10.38
10.38
10.38
growth rate 35.1% 0.0% 0.0% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (43.35)

YOY Growth Grade:

F (13.60)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 2.02 2.03 5.50
EPS / Growth 1.52

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 40.0% 50.0% 100.0%
Future PE 2.02 4.34 69.17
Future EPS 44.00 87.71 1,557.50
Value Price
MOS %
21.97
613.2%
94.09
2,954.9%
26,631.11
864,546.4%
MOS Price 10.98 47.05 13,315.55
IRT 1.32 1.23 1.01

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.